id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-253422-m18ngwbt	Trimarchi, Hernán	COVID-19 and acute kidney injury in pediatric subjects: is there a place for eculizumab treatment?	2020-09-29		.txt	text/plain	976	47	39	One of the reasons we found this case of particular interest is that it reminds us of a similar experience by one of the authors who observed a dramatic effect of eculizumab in a 4-year-old child with diffuse proliferative lupus nephritis who developed complement-mediated TMA and AKI [6] . She fully recovered but needed chronic eculizumab treatment for atypical hemolytic uremic syndrome (aHUS). In both cases the initial disease was a severe multisystem inflammatory syndrome due to SARS-CoV-2 or systemic lupus erythematosus. He was admitted with severe diffuse bilateral SARS-CoV-2 pneumonia [9] and elevated D-dimer and fibrinogen concentrations, suggesting a pro-coagulant state due to pulmonary microthrombosis, as described in autopsies of subjects with COVID-19 infections [1] , despite ongoing chronic eculizumab treatment. However, while waiting for further follow-up, the present report deserves our utmost interest because it highlights the role of the complement system activation in SARS-COV-2 infection and the pharmacological interventions to attenuate the micro-thrombotic complications associated with COVID-19. Eculizumab, SARS-COV-2 and atypical hemolytic uremic syndrome	./cache/cord-253422-m18ngwbt.txt	./txt/cord-253422-m18ngwbt.txt